



There is increasing evidence that angiotensin II (Ang II), a major 
regulator of blood pressure and cardiovascular homeostasis, 
is involved in the regulation of cell proliferation, angiogenesis, 
inflammation and tissue remodeling, which suggests that this peptide 
might also play a role in cancer [1]. The renin-angiotensin system 
(RAS) has been characterized extensively in hypertension and 
atherosclerosis, but recently its relevance to the fields of oncology 
and hematology are being studied [2, 3].
The RAS pathway mediates its effect primarily via angiotensinogen, 
angiotensin I (Ang I), and Ang II. The enzyme renin converts 
angiotensinogen to the decapeptide Ang I, which is transformed into 
the octapeptide Ang II by the exopeptidase angiotensin I-converting 
enzyme (ACE) [4]. Components of RAS are expressed in several adult 
organs including the liver, kidney, pancreas, brain and reproductive 
organs. It is the paracine mechanisms of locally expressed RAS, not 
in its circulating counterpart, that appear important for tumourigenesis 
[5, 6]. Ang II is the main effector of the RAS and it alternatively 
binds to either Ang II-type 1 receptors (AGTR1) or Ang II-type 2 
receptors (AGTR2). The AGTR1 and AGTR2 can act as antagonists, 
and mediate effects on cell migration and proliferation of metastatic 
cancer cells and hemopoietic stem-progenitor cells [7]. Components 
of the RAS are frequently differentially expressed in various cancers 
in comparison with their corresponding non-malignant tissue. In 
particular, over-expression of AGTR1 [3].
Studies of knockout mice for ACE as well as other RAS components 
such as angiotensinogen, renin, AGTR1 and AGTR2 have further 
implicated a regulatory role for the RAS in hematopoiesis [8]. These 
mice have exhibited not only phenotypes related to blood pressure, 
but also demonstrated defects in development and in hematopoietic 
system [9]. ACE null mice are mildly anemic, so it is presumed that 
the lack of systemic or local production of Ang II has a detrimental 
effect on erythropoiesis [10]. The AGTR1 belong to the G protein- 
coupled receptor family and typically activates phospholipase C 
(PLC). It maps to chromosome 3 [11].
Acute leukemias are hemopoietic neoplasms characterized by 
accumulation of blast cells in the bone marrow and peripheral blood 
[12]. Acute lymphoblastic leukemia (ALL) is a malignant disease 
characterized by the accumulation of lymphoblasts and it may be B 
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or T lineages and the first attempt at classifying ALL was the French-
American-British (FAB) morphological criteria that divided ALL into 
3 subtypes (L1, L2 and L3) based on cell size, cytoplasm, nucleoli, 
vacuolation and basophilia. In 1997, the World Health Organization 
proposed a composite classification in an attempt to account for 
morphology and cytogenetic profile of the leukemic blasts and 
identified three types of ALL: B lymphoblastic, T lymphoblastic and 
Burkitt-cell leukemia. Later revised in 2008, Burkitt-cell leukemia was 
eliminated as it is no longer seen as a separate entity from Burkitt 
lymphoma, and B-lymphoblastic leukemia was divided into two 
subtypes: B-ALL with recurrent genetic abnormalities and B-ALL not 
otherwise specified. B-ALL with recurrent genetic abnormalities is 
further delineated based on the specific chromosomal rearrangement. 
In 2016, two new provisional entities were added to the list of 
recurrent genetic abnormalities and the hypodiploid was redefined as 
either low hypodiploid or hypodiploid with TP53 mutations. In adults, 
B-cell ALL accounts for ~75% of cases while T-cell ALL comprises 
the remaining cases [12, 13]. Acute myeloid leukemia (AML) is a 
malignant clonal disorder of immature cells in the hemopoietic 
hierarchical system and is confirmed by an excess of primitive blast 
cells in the bone marrow required to be at least 20% and there is 11 
subtypes of AML [14, 15]. Diagnosis is established by the presence 
of 20% or more lymphoblasts in the bone marrow or peripheral blood. 
Evaluation for morphology, flow cytometry, immunophenotyping and 
cytogenetic testing is valuable both for confirming the diagnosis and 
risk stratification. Lumbar puncture with CSF analysis is standard 
of care at the time of diagnosis to evaluate for CNS involvement. 
If the CNS is involved, brain MRI should be performed. Other 
evaluation includes complete blood count with differential and smear 
to evaluate the other hematopoietic cell lines, coagulation profiles 
and serum chemistries. Baseline uric acid, calcium, phosphate and 
lactate dehydrogenase should be recorded to monitor for tumor lysis 
syndrome. Morphology remains the method by which acute leukemia 
is initially detected and is the major aid with cytochemical reaction 
in distinguishing between acute lymphoblastic leukemia and acute 
myeloid leukemia [15]. Yet, the RAS has not been fully elucidated in 
patients with acute leukemia.
The present study aimed to study serum level of angiotensin 
II receptor type 1 and the soluble angiotensin converting enzyme 
(CD143) in patients with acute leukemia in order to extrapolate their 
possible prognostic value. Individuals submitted to this study were 
divided into three groups: group I – involved 20 healthy volunteers 
clinically free from hypertension or sarcoidosis (control group), their 
mean age was 33.25 years and were chosen from the stuff members 
of MRI, Alexandria University, and clinical research center, Faculty 
of Medicine, Alexandria University and their relatives, group 
II – involved 20 patients of newly diagnosed AML and group III – 
involved 20 patients of newly diagnosed ALL. Patients in group II 
and III were of matched age as the control group and were recruited 
from Hematological Department, MRI, Alexandria University and 
clinical research center, Faculty of Medicine, Alexandria University. 
An informed consent was taken from all contributors in this study.
Patients with AML received 3 + 7 protocol of induction including: 
daunomycin 45 mg/m2 for 3 days, cytosine arabinoside 
100 mg/m2 × 2/day for 7 days. Patients with ALL received induction 
protocol as follows: vincristine 1.4 mg/m2 days 1, 8, 15, 22, 
prednisolone 1 mg/kg/day × 28 days, doxorubicin 25 mg/m2 days 1, 
2, 3. After completion of the cycles and restoration of bone marrow 
cellularity, bone marrow aspiration was done. Patients who achieved 
complete remission had a BM blasts less than 5%. Those who did not 
achieve complete remission received a 2nd induction cycle.
To all patients the following investigations were done:
1 – full history recording, 2 – thorough clinical examination, 3 – 
routine laboratory investigations including: complete blood picture, 
liver and kidney functions, 4 – radiological investigations including: 
chest x ray, abdominal ultrasound and ECG study, 5 – bone marrow 
examination [16], 6 – determination of serum human ACE by ELISA 
method [17] and 7 – determination of serum human Ang IIT1R by 
ELISA method [17].
Statistical analysis
Statistical analysis was carried out using SPSS statistics software 
version 20. Quantitative data were tested for normality using 
Kolmogorov-Smirnov test. Abnormally distributed data was given 
as range (minimum-maximum). Non-parametric statistical tests of 
significance were applied; Mann-Whitney test was used to compare 
two independent groups. All applied statistical tests of significance 
were two-tailed. Receiver operating characteristic (ROC), carried 
out using MedCalc statistical software, was used to evaluate the 
diagnostic and prognostic accuracy of a test to correctly pick cured 
and non-cured subjects. The larger the area under the curve (AUC) 
i.e. closer to 1, the better the performance of a diagnostic test. 
Youden index was used to find the cut-off point i.e. the point that 
gives maximum correct classification. At this cut-off point, sensitivity; 
defined as the probability that the test is positive in patients with 
the disease and specificity; defined as the probability that the test 
is negative in patients without the disease were determined. Also, 
positive predictive value; defined as probability that the patient has 
the disease when the test is positive and negative predictive value; 
defined as probability that the patient will not have the disease when 
the test is negative were identified.
Biochemical Results
ACE activity (U/L) in normal control subjects and patients 
groups with either AML or ALL before and after therapy
As presented in table I, the statistical analyses of these results 
revealed that the activity of ACE (U/L) in patients groups with either 
AML or ALL before therapy was significantly higher than in control 
group. After therapy, the activity of this enzyme in both groups of 
patients was significantly decreased but still significantly higher than 
in normal control subjects.
Ang IIT1R level (U/L) in normal control subjects and pa- 
tients groups with either AML or ALL before and after 
therapy
As presented in table II, the statistical analyses of these results 
revealed that the level of Ang IIT1R (U/L) in patients groups with 
either AML or ALL before therapy was significantly higher than in 
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control group. After therapy, it was noticed that the level of this 
receptor in both groups of patients was significantly decreased than 
in their corresponding values before therapy and still significantly 
higher than in normal control group.
Liver function levels in normal control subjects and 
patients groups with either AML or ALL
As presented in table III, the statistical analyses of these results 
revealed that the mean values of indirect bilirubin (mg/dl), total 
bilirubin (mg/dl) and SGPT (u/l) concentrations in both groups of 
patients were significantly higher than normal control group. In 
addition, the concentrations of direct bilirubin (mg/dl) as well as SGOT 
(u/l) in patients with ALL were significantly higher than normal control 
group. On the other hand, serum albumin (mg/dl) concentrations 
in both groups of patients were significantly lower than in normal 
subjects. Kidney function levels in normal control subjects and 
patients groups with either AML or ALL.
As presented in table IV, the statistical analyses of these results 
revealed that in both groups of patients, the mean values of creatinine 
(mg/dl) concentrations were significantly lower than in normal control 
group.
Sodium, Potassium, Calcium and Phosphorus levels in 
normal control subjects and patients groups with either 
AML or ALL
As presented in table V, the statistical analyses of these results 
revealed that the mean values of sodium, potassium, calcium 
and phosphorus concentrations in both groups of patients were 
significantly lower than in normal control group.
Hematological Results
Mean values of WBC count (x10e9), Platelets count 
(x10e9) and Hemoglobin concentration (g/dl) in normal 
control subjects and patients groups with either AML or 
ALL
As presented in table VI, the statistical analyses of these results 
revealed that the mean values of WBCs count in AML and ALL patients 
were higher than in control group. On the other hand, Platelets count 
and Hb concentration in both groups of patients were significantly 
lower than in normal subjects.
Mean values of blasts cells% in normal control group and 
patients group with either AML or ALL before and after 
therapy
As presented in table VII, the statistical analyses of these results 
revealed that the blast cells % in patients with either AML or 
ALL before therapy was significantly higher than in control group. 
After therapy, the % of blast cells in both groups of patients were 
significantly decreased compared to their corresponding values 
before therapy and still significantly higher than in control group.
Correlation between ACE activity (U/L) and all studied 
parameters
As presented in table VIII, ACE activity (U/L) in serum of AML patients 
group showed a significant positive correlation with blast cells % at 
presentation.
Table I. Statistical analysis of serum ACE activity (U/L) in normal control subjects and patients groups either with AML or ALL 
before and after therapy 
Normal control (n = 20)
Patients with AML (n = 20) Patients with ALL (n = 20)
Before therapy After therapy Before therapy After therapy
ACE (U/L)
Range 43.0-47.25 48.25-71.0 43.0-65.0 49.25-69.0 43.75-63.0
Mean ± SE 45.51 ± 0.29 53.56 ± 1.20 48.12 ± 1.02 53.10 ± 1.81 49.20 ± 1.61
p1 < 0.001
* 0.031* < 0.001* < 0.001*
p2 < 0.001
* 0.005*
p1: p comparing mean values with control group; p2: p comparing mean values before and after therapy
*: Statistically significant at p ≤ 0.05
Table II. Statistical analysis of serum Ang IIT1R concentration (U/L) in normal control subjects and patients groups either with AML 
or ALL before and after therapy 
Normal control (n = 20)
Patients with AML (n = 20) Patients with ALL (n = 20)
Before therapy After therapy Before therapy After therapy
AngIIT1R (U/L)
Range 324.0-360.0 370.0-520.0 336.0-400.0 378.0-550.0 338.0-392.0
Mean ± SE 344.60 ± 1.61 418.33 ± 7.39 358.81 ± 3.50 432.0 ± 18.14 361.40 ± 5.66
p1 < 0.001
* 0.001* < 0.001* 0.016*
p2 < 0.001
* 0.004*
p1: p comparing mean values with control group; p2: p comparing mean values before and after therapy
*: Statistically significant at p ≤ 0.05
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Table III. Statistical analyses of liver function in normal control subjects and patients groups either with AML or ALL 
Normal control (n = 20) Patients with AML (n = 20) Patients with ALL (n = 20)
Direct bilirubin (mg/dl)
Range 0.10-0.20 0.10-0.40 0.10-1.0
Mean ± SE 0.12 ± 0.01 0.16 ± 0.02 0.33 ± 0.09
P1 p1 = 0.347  p2 = 0.008
*
Indirect bilirubin (mg/dl)
Range 0.15-0.30 0.10-0.50 0.10-0.60
Mean ± SE 0.23 ± 0.01 0.36 ± 0.02 0.34 ± 0.05
P1 p1 <0.001
*
  p2 = 0.011
*
Total bilirubin (mg/dl)
Range 0.30-0.40 0.30-0.80 0.30-0.90




Total serum protein (mg/dl)
Range 6.80-7.50 1.90-9.50 2.0-8.30
Mean ± SE 7.21 ± 0.04 6.87 ± 0.32 6.52 ± 0.55
P1 p1= 0.640 p2 = 0.411
Albumin (mg/dl)
Range 3.90–4.60 1.80-4.30 2.40-3.50





Range 12.0-25.0 11.0-55.0 12.0-141.0
Mean ± SE 17.45 ± 0.82 21.67 ± 1.96 46.0 ± 12.83
P1 p1 = 0.133 p2 = 0.010
*
SGPT (u/l)
Range 14.0-25.0 10.0-82.0 7.0-89.0
Mean ± SE 18.35 ± 0.74 31.11 ± 3.60 46.90 ± 8.36
P1  p1 = 0.002
* p2 = 0.005
*
 p1: p comparing mean values with control group; *: Statistically significant at p ≤ 0.05
Table IV. Statistical analyses of kidney function in normal control subjects and patients groups either with AML or ALL 
Normal control (n = 20) Patients with AML (n = 20) Patients with ALL (n = 20)
Alkaline phosphatase (U/L)
Range 65.0-85.0 40.0-113.0 40.0-92.0
Mean ± SE 76.35 ± 1.15 79.52 ± 3.18 69.30 ± 5.49
P1 p1= 0.440  p2 = 0.193
Uric acid (mg/dl)
Range 2.30-3.50 1.90-5.10 1.30-6.0
Mean ± SE 2.87 ± 0.09 2.78 ± 0.18 2.89 ± 0.43
P1 p1= 0.076 p2 = 0.414
Urea (mg/dl)
Range 22.0-35.0 13.0-42.0 24.0-35.0
Mean ± SE 27.90 ± 0.88 26.74 ± 1.33 28.56 ± 1.38
P1 p1= 0.531 p2 = 0.673
Creatinine (mg/dl)
Range 1.20-1.60 0.40-1.90 0.50-1.40
Mean ± SE 1.38 ± 0.03 1.03 ± 0.09 0.97 ± 0.10
P1 p1 = 0.003
* p2 <0.001
*
 p1: p value for comparing between control and patients; *: Statistically significant at p ≤ 0.05
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Table V. Statistical analyses of Sodium, Potassium, Calcium and Phosphorus in normal control subjects and patients groups either 
with AML or ALL 
Normal control (n = 20) Patients with AML (n = 20) Patients with ALL (n = 20)
Sodium (meq/l)
Range 130.0-145.0 114.0-139.0 120.0-135.0
Mean ± SE 138.95 ± 0.75 132.48 ± 1.15 128.60 ± 1.90
P1 p1 < 0.001
* p2 < 0.001
*
Potassium (meq/l)
Range 3.50-4.90 2.80-5.10 3.30-5.10
Mean ± SE 4.33 ± 0.08 3.69 ± 0.12 3.72 ± 0.19




Range 9.50-10.60 7.10-9.60 4.30-9.70
Mean ± SE 10.20 ± 0.07 8.53 ± 0.14 8.28 ± 0.49
P1 p1 < 0.001
* p2 < 0.001
*
Phosphorus (meq/l)
Range 4.80-5.30 2.70-5.10 2.50-4.60
Mean ± SE 5.04 ± 0.03 3.95 ± 0.10 3.90 ± 0.22
P1 p1 < 0.001
* p2 < 0.001
*
 p1: p value for comparing between control and patients *: Statistically significant at p ≤ 0.05
Table VI. Statistical analyses of hematological parameters in normal control subjects and patients groups either with AML or ALL
Normal control (n = 20) Patients with AML (n = 20) Patients with ALL (n = 20)
WBCs count (x10e9)
Range. 3.50-10.0 0.41-86.20 1.03-86.16
Mean ± SE 7.21 ± 0.40 15.40 ± 4.19 22.58 ± 9.95
P1 0.208 0.397
Platelets count (x10e9)
Range 127.0-328.0 4.0-66.0 8.0-44.0
Mean ± SE 233.0 ± 11.96 22.42 ± 2.76 28.34 ± 3.75
P1 < 0.001* < 0.001*
HB concentration (g/dl)
Range 12.40-15.50 4.40-11.20 5.40-10.0
Mean ± SE 13.23 ± 0.18 8.11 ± 0.26 7.71 ± 0.49
P1 < 0.001* < 0.001*
 p1: p comparing mean values with control group *: Statistically significant at p ≤ 0.05
Table VII. Statistical analyses of blasts cells % in normal control subjects and patients groups either with AML or ALL before and 
after therapy
Normal control (n = 20)
Patients with AML (n = 20) Patients with ALL (n = 20)
Before therapy After therapy Before therapy After therapy
Blast cells %
Range 1.0-3.0 10.0-96.0 1.0-60.0 15.0-90.0 2.0-20.0
Mean ± SE 1.45 ± 0.14 73.93 ± 3.68 8.81 ± 2.34 70.90 ± 6.73 10.50 ± 2.27
p1 < 0.001
* < 0.001* < 0.001* < 0.001*
p2 < 0.001
* 0.005*
p1: p comparing mean values with control group p2: p comparing mean values before and after therapy
*: Statistically significant at p ≤ 0.05
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In ALL patients groups, it was noticed that there was a significant 
positive correlation between ACE activity (U/L) with blast cells 
% and Hb concentration (g/dl), and was reversely correlated with 
Phosphorus concentration (meq/l).
Correlation between Ang IIT1R concentration (U/L) and 
all studied parameters
As presented in table IX, Ang IIT1R concentration (U/L) in serum 
of AML patients group showed a significant positive correlation with 
blast cells % and urea concentration (mg/dl) at presentation.
In ALL patients groups, it was noticed that there was a significant 
positive correlation with blast cells %, and was reversely correlated 
with WBCs count (x10e9) and Sodium concentration (meq/l).
Comparison between the values of serum ACE activity 
(U/L) and Ang IIT1R concentration (U/L) as diagnostic 
markers for acute leukemia
As presented in table X and fig. 1, serum ACE activity (U/L) showed 
significant AUC (100%, p < 0.001) with sensitivity 100% and specificity 
100% at a cut off value (47.25 U/L).
Serum Ang IIT1R concentration (U/L) showed significant AUC 
(100%, p < 0.001) with sensitivity 100% and specificity 100% at a cut 
off value (360 U/L).
Prognostic values of serum ACE activity (U/L) and Ang 
IIT1R concentration (U/L) in acute leukemia patients
As presented in table XI, XII and fig.2, fig.3, Kaplan-Meier 
DFS curves for acute leukemia patients groups revealed that, 
patients with elevated levels of serum ACE activity (U/L) and Ang 
IIT1R concentration (U/L) than their corresponding cut off points were 
Fig. 1. Graphical representation of the ROC curves for serum 
ACE activity (U/L) and Ang IIT1R concentration (U/L) in acute 
leukemia patients before therapy
Table VIII. Correlation between ACE activity (U/L) and all studied parameters
ACE activity (U/L)
AML patients ALL patients
rs p rs p
Blast cells % 0.797* < 0.001 0.689* 0.028
WBCs count (x10e9) 0.073 0.718 -0.237 0.510
HB concentration (g/dl) 0.006 0.978 0.670* 0.034
Platelets count (x10e9) 0.044 0.829 -0.535 0.111
Direct bilirubin concentration (mg/dl) 0.247 0.215 -0.430 0.251
Indirect bilirubin concentration (mg/dl) -0.376 0.053 -0.405 0.246
Total bilirubin concentration (mg/dl) -0.147 0.464 -0.165 0.648
Total serum protein concentration (mg/dl) -0.036 0.857 -0.210 0.561
Albumin concentration (mg/dl) -0.159 0.428 0.198 0.583
SGOT concentration (u/l) 0.117 0.562 0.598 0.068
SGPT concentration (u/l) -0.083 0.680 0.615 0.059
Alkaline phosphatase concentration (u/l) -0.324 0.099 -0.379 0.280
Uric acid concentration (mg/dl) 0.203 0.311 0.232 0.519
Urea concentration (mg/dl) -0.162 0.421 0.518 0.125
Creatinine concentration (mg/dl) -0.058 0.773 -0.117 0.748
Sodium concentration (meq/l) 0.032 0.874 -0.437 0.207
Potassium concentration (meq/l) -0.220 0.271 0.022 0.952
Calcium concentration (meq/l) 0.196 0.328 0.257 0.474
Phosphorus concentration (meq/l) 0.069 0.733 -0.659* 0.038*
rs: Spearman coefficient; *: Statistically significant at p ≤ 0.05
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Table IX. Correlation between Ang IIRT1 concentration (U/L) and all studied parameters
AngIIT1R concentration (U/L)
AML patients ALL patients
Coff. p Coff. p
Blast cells % rs = 0.873
* < 0.001 rs = 0.681
* 0.030
WBCs count (x10e9) rs = 0.094 0.641 rs = -0.806
* 0.005
HB concentration (g/dl) r = 0.216 0.279 r = 0.029 0.938
Platelets count (x10e9) rs = -0.052 0.798 rs  = -0.512 0.130
Direct bilirubin concentration (mg/dl) rs = 0.056 0.781 rs = -0.365 0.299
Indirect bilirubin concentration (mg/dl) rs = -0.027 0.895 rs= -0.279 0.435
Total bilirubin concentration (mg/dl) rs = 0.019 0.924 rs = -0.081 0.825
Total serum protein concentration (mg/dl) rs = -0.180 0.370 rs = -0.080 0.827
Albumin concentration (mg/dl) rs = 0.063 0.755 rs = 0.129 0.722
SGOT concentration (u/l) rs = 0.253 0.204 rs = -0.115 0.751
SGPT concentration (u/l) rs = -0.226 0.257 rs = -0.401 0.250
Alkaline phosphatase concentration (u/l) rs = -0.328 0.095 rs = 0.201 0.578
Uric acid concentration (mg/dl) rs = -0.116 0.563 rs = -0.018 0.960
Urea concentration (mg/dl) rs = 0.428
* 0.026* rs = 0.073 0.841
Creatinine concentration (mg/dl) rs = 0.135 0.502 rs = -0.140 0.699
Sodium concentration (meq/l) rs = -0.248 0.212 rs  = -0.838
* 0.002*
Potassium concentration (meq/l) rs = -0.244 0.220 rs = 0.332 0.348
Calcium concentration (meq/l) rs = 0.073 0.716 rs = -0.079 0.828
Phosphorus concentration (meq/l) rs = 0.099 0.624 rs = 0.215 0.550
 rs: Spearman coefficient *: Statistically significant at p ≤ 0.05 
Fig. 2. Kaplan-Meier disease free survival of serum ACE activity (U/L) for acute leukemia patients
Fig. 3. Kaplan-Meier disease free survival of serum Ang IIT1R concentration (U/L) for acute leukemia patients
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significantly different from those with low levels according to log rank 
test (p < 0.001* and p < 0.001* respectively).
Discussion
The physiology of angiotensin II continues to be a major field of 
investigation. Recently reported mechanisms suggest that it has 
growth-promoting factor and cytokine like properties in addition to its 
vasoconstrictor actions.
Some of the pathophysiological effects of Ang II may be mediated 
through activation of the transcription factor nuclear factor ΚB (NF 
ΚB) which participates in a variety of inflammatory responses as well 
as neoplasia [18].
In addition to ACE dependent pathways of Ang II formation, non ACE 
pathways have been demonstrated, namely chymase which is a 
chymotypsin-like serine protease which may represent an improtant 
mechanism for the conversion of Ang I to Ang II in tissues and in 
vasculature. In this regard, mast cell chymase immunostaining could 
identify acute myeloid leukemia [19].
The Ang II T1R has recently been identified, and its mechanisms of 
action continue to be elaborated.
On the other hand, Ang II T1R mediated over-production of ROS has 
potent growth-promoting actions by exerting positive feedback effects 
that amplifies its signaling in leucocytes and monocytes. Agonist- 
induced activation of the Ang II T1R participates in promotion of 
tumor progression and metastasis though its growth-promoting and 
proangiogenic Ang II T1R [20].
In the present study, the median serum level of ACE was significantly 
higher in leukemic patients before therapy compared to the control. 
In the meantime, the level significantly declined post chemotherapy 
compared to the pre-treatment levels, yet it did not reach the control 
level in some patients. This reflects the leukemogenic effect of 
this enzyme especially in patients with AML, this also proved the 
positive correlation between serum level of ACE and blast percent 
denoting that these leukemic blasts are incriminated in its production. 
Moreover, an interindividual variability in the serum level of the 
enzyme was observed in leukemic patients which could be attributed 
to the possible interplay of ACE gene polymorphism. This is in 
agreement with Angela et al. [21] who reported that ACE insertion/
deletion (I/D) polymorphism plays important role in breast cancer risk 
and disease-free survival in Caucasian postmenopausal women, the 
D/D carries having an increased risk of developing breast cancer. 
The ACE gene is located in chromosome 17 q 23 and has many 
polymorphisms. The most commonly studied is a 287 bp insertion/
deletion polymorphism in intron 16 that accounts for 50% of the 
variability in circulating ACE [22, 23].
Moreover, several studies have shown that Ang II acts as a growth 
factor in normal and breast cancer cells through phospholipase C 
activation [24]. The deletion polymorphism of ACE gene leads to 
increased serum levels [25]. Alternatively, other as yet unidentified 
gene loci in linkage disequilibrium with the ART1 1166 variant may 
account for the different serum levels of the enzyme.
In the present study, we observed that patients with the maximal 
level of ACE before therapy did not reach a level nearing with the 
control, but the level remained higher than the control reflecting a 
state of failure of induction chemotherapy in reducing the burden 
of leukemic cells. This denotes a more aggressive leukemic blasts 
possibly bearing the CD34+ immunophenotype and necessitating a 
more aggressive induction chemotherapy protocol.
Our finding confirms the study of Jokubaitis et al. [26] who reported 
that ACE (CD143) marks hemopoietic cell with hemopoietic stem cell 
characteristics in adult haemopoietic tissues.
The present study is also supported by the report of Aksu 
et al. [27] who demonstrated that AML cells overexpress ACE (CD 
Table X. The area under the ROC curves, sensitivity and specificity for serum ACE activity (U/L) and Ang IIT1R concentration (U/L) 
in acute leukemia patients before therapy 
Before therapy Area under the curve Asymptomatic significance Cut off values Sensitivity % Specificity %
ACE activity (U/L) 100% < 0.001 47.25 100.0 100.0
Ang IIT1R concentration (U/L) 100% < 0.001 360 100.0 100.0
Table XI. Test of significance of disease free survival of serum ACE activity (U/L) in acute leukemia patients 
ACE (U/L) Mean %
Log rank
c2 p
≤ 50.25 14.75 50.0
17.102* <0.001*
> 50.25 2.84 0.0
Table XII. Test of significance of disease free survival of serum Ang IIT1R concentration (U/L) in acute leukemia patients 
Ang IIT1R (U/L) Mean %
Log rank
c2 p
≤ 386 15.18 54.5
14.496* < 0.001*
> 386 3.12 0.0
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143), an observation that explains, in part, the relative refractoriness 
of leukemic cells to the inhibitory effects of chemotherapeutic 
drugs. Their group hypothesized the presence of a local bone marrow 
renin-angiotensin system affecting physiological and neoplastic 
blood cell formation. The local RAS has been defined as an autocrine- 
paracrine system within the hematopoietic lineage and marrow 
stromal cells [28] that may be involved in neoplastic hematopoiesis 
and leukemogenesis [29, 30, 31].
In the present study, a positive correlation was found between ACE 
levels and bone marrow blasts, a finding which is congruent with Aksu 
et al. [27]. Moreover, several authors reported that renin mRNA was 
found in leukemic blast cells [29, 30].
Our results were as well explained by Abali et al. [29] who stated 
that ACE degrades a tetra-peptide called ACSDKP (goralatide), a 
negative hematopoietic regulator, hence while peripheral blood ACE 
levels increase, blast percentages in the bone marrow accumulate 
and migrate to the circulation. Therefore, ACE hyperfunction may 
lead to the enhanced goralatide metabolism, which in turn lowers 
its level in the bone marrow micro-environment, abolishing the anti- 
proliferative effect of the peptide on the hematopoietic cells and 
leukemic blasts [30].
Leukemogenesis is a multistep and multifactorial process which 
includes activation of oncogenic mutations in signal transduction 
pathways, conferring a proliferative survival advantage on leukemic 
cells over normal hematopoietic profanities. Angiogenesis which is 
neovascularization is one of these crucial pathways in the biology 
of acute leukemia. In addition to conversion of Ang I to Ang II, ACE 
breaks down bradykinin (BK) into inactive peptides. Several lines 
of evidence underline the putative role of BK in the modulation 
of angiogenesis, hence BK activates angiogenesis independent of 
VEGF pathway [32].
Similarly, it has been reported that AngII activates the mitogen- 
activated protein kinase pathway (MAPK), which has a mitogenic 
effect [27].
On the other hand, recent studies have shown that Ang II and Ang 
(1-7) also have regulatory effect on tissue regeneration, cellular 
proliferation and growth factor release [33, 34]. In vivo studies have 
shown that Ang II and Ang (1-7) peptides increased hematopoietic 
recovery after myelosuppression on multiple blood cell lineages [35, 
36]. This could explain the post chemotherapy raised level of 
ACE despite being lower than pre-treatment level. In our study, the 
enhanced enzyme activity could be beneficial in terms of bone marrow 
regeneration after the nadir induced by induction chemotherapy. This 
key component in the renin-angiotensin system, ACE, in the normal 
human hemangioblast, supports the critical nature of this enzyme in 
hematopoietic development [37].
In support of this finding, Shen et al. [37] working on ACE knockout 
mice, stated that these mice have hematologic developmental 
defects. They added that an animal lacking all ACE is very different 
from a wild type animal and can be modeled as representing an 
extreme complicated phenotype with cardiovascular, reproductive, 
hematologic and developmental defects.
Another possibility is that post chemotherapy production of ACE 
might be enhanced by cells other than leukemic blasts. These cells 
are namely monocytes and macrophages. In this context, Shen et 
al. [37] forwarded substantial evidence that tumor resistance of ACE 
Knockout mice exhibits a different immune response as compared to 
wild type animals. Their data include the finding that their knockout 
mice develop greater numbers of CD8+ cytotoxic T lymphocytes 
directed at tumor antigens. In addition, the cytokine levels in these 
mice are different from those in wild type animals.
Similarly, macrophages express Ang II T1R and release angiogenic 
cytokines, including VEGF, which promote angiogenesis [38]. In this 
regard, it has been reported that pharmacological blockade of Ang 
II T1R also reduced tumor angiogenesis, growth and metastasis 
[39, 40].
Moreover, it has been reported that mechanisms of Ang IIT1R 
activation, such as receptor transactivation of tyrosine kinase 
receptors and stimulation of ROS production suggest that Ang II has 
growth factor and cytokine-like properties. Receptor transactivation 
may be defined as that process whereby ligand stimulation of one 
receptor leads to activation of another distinct receptor.
In the present study, a significant decline in serum levels of Ang 
IIT1R in patients after therapy, approximately reaching the control 
level was observed. This could be explained by the decrease in 
blast percentage by effective chemotherapy at one hand, and by the 
possibility that the soluble form of the receptor formed a ligand to the 
remaining receptors expressed on remaining blasts or leukocytes. 
Hence, they block the receptors leading to abrogation of the signal 
transduction pathways and dampening of their activation.
In the current study we examined the diagnostic significance of ACE 
activity (U/L) and Ang IIT1R concentration (U/L) by ROC curve. 
The curve showed that both parameters were excellent diagnostic 
markers of acute leukemia as was indicated by asymptomatic 
significance and very high area under the curve (100%, 100% 
respectively). The optimum cut off value of ACE activity (U/L) and 
Ang IIT1R concentration (U/L) were with a corresponding sensitivity 
100% and specificity 100% for both parameters.
For the first time, we could define a prognostic value for estimating 
the levels of ACE activity (U/L) and Ang IIT1R concentration (U/L) in 
patients with acute leukemia. The Kaplan-Meier disease free survival 
curve specified a cut off level for ACE < or > than 50.25 U/L with 
statistical significance (p < 0.00). This was true for Ang IIT1R as a 
cut off value of below or above 386 U/L could discriminate between 
a higher mean disease free survival of 24 months compared to 14 
months in patients with higher level above the cutoff point and the 
difference was statistically significant (p < 0.001).
In the present study, a lower serum potassium was observed in 
patients with acute leukemia, whether ALL or AML, yet AML patients 
had even lower levels in AML reflecting hypokalemia. We attributed 
this decrease in serum potassium to a paraneoplastic syndrome or 
disturbed electrolytes in these patients.
In accordance to our findings, Wulf et al. [41] reported on 
paraneoplastic hypokalemia in AML. They stated that it was due to 
enhanced renin activity in AML blast cells.
As regards serum albumin in level, it was significantly decreased in 
patients with both types of acute leukemia denoting liver dysfunction 
due to leukemic infiltration. Another possibility is that patients with 
acute leukemia are cachectic and suffer from a negative protein 
balance, especially with the presence of fever and loss of weight.
In agreement with our results, a low serum albumin is considered as 
a poor prognostic marker in AML [42].
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Regarding serum sodium level, the present study exhibited a 
significant decrease in serum sodium levels in patients with acute 
leukemias and the control. This could be ascribed to paraneoplastic 
production of antidiuretic hormone, a syndrome known as “syndrome 
of inappropriate antidiuretic hormone” release by the leukemic blasts. 
This syndrome is sometimes aggravated by chemotherapeutic drugs, 
especially those used in treating ALL.
The novelty of this study is that it evaluates the impact of induction 
chemotherapy on serum ACE and soluble Ang II T1R in patients with 
acute leukemia. Other studies were in-vitro studies.
Hence our study indicates a causal relationship between RAS and 
acute leukemia imparting that manipulating the renin-angiotensin 
pathways and targeting its receptors could be exploited as adjuvant 
therapy in these patients.
Conclusion
To the best of our knowledge the above study is the first to investigate 
the levels of serum ACE and its soluble receptor1 in patients with 
acute leukemia. We may conclude that estimating the serum level of 
ACE and soluble Ang IIT1R might be of informative diagnostic and 
prognostic value.
The findings of the present study make AR blockers and ACE 
inhibitors as a targeted option in the management of acute leukemia.
Recommendations
From the results of the present study we recommend the following:
1. Estimation of Ang II T1R and ACE levels in acute leukemia is 
of value in deciding the treatment protocol.
2. Further study on the other components of the RAS system 
is warranted.
3. Further studies on the impact of RAS on other hemopoietic 
neoplasms are to be envisaged namely the chronic leukemias 
and lymphomas.
4. Novel clinical applications of ACE inhibitors and Ang II T1R 
blockade in the management of acute leukemia is worthwhile.
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